Apathy and depression: separate factors in Parkinson's disease.
Apathy and depression: separate factors in Parkinson's disease.
复制标题
DOI：
10.1017/s1355617711001068
复制
发表时间：
2011-11
影响因子：
2.6
通讯作者：
Bowers, Dawn
中科院分区：
文献类型：
--
作者：
Kirsch-Darrow, Lindsey;Marsiske, Michael;Okun, Michael S.;Bauer, Russell;Bowers, Dawn
本研究的目的是测试的假设，冷漠和抑郁症是分离的帕金森病（PD）进行验证性因素分析（CFA）的项目，从两个常用的情绪量表。共161例非痴呆PD患者（年龄= 64.1 ± 8.4岁）接受了冷漠量表和贝克抑郁量表-II。假设项目加载到四个因素：（1）冷漠因素代表失去动力，（2）烦躁情绪因素代表悲伤和消极，（3）兴趣/快乐因素的损失代表冷漠和抑郁的共同特征，（4）身体因素代表身体投诉。结果表明总体CFA模型拟合良好，χ2（128，N = 146）= 194.9; p<.01。RMSEA为.060（p = .16）。四因素模型在p <0.001时显著优于所有替代嵌套模型，包括代表“抑郁”的总体单因素模型。结果支持的概念，冷漠和抑郁症是离散的结构。我们建议一个“基于因素”的评分冷漠量表和贝克抑郁量表-II，解开相关的冷漠，抑郁，重叠的症状，和躯体的投诉症状。这种评分在提供关于差别待遇选择的有用信息方面可能很重要。
The objective of this study was to test the hypothesis that apathy and depression are dissociable in Parkinson disease (PD) by conducting a confirmatory factor analysis (CFA) of items from two commonly used mood scales. A total of 161 non-demented PD patients (age = 64.1; ± 8.4 years) were administered the Apathy Scale and the Beck Depression Inventory-II. Items were hypothesized to load onto four factors: (1) an apathy factor representing loss of motivation, (2) dysphoric mood factor representing sadness and negativity, (3) loss of interest/pleasure factor representing the features common to both apathy and depression, and (4) a somatic factor representing bodily complaints. Results indicated a good fit for the overall CFA model, χ2 (128, N = 146) = 194.9; p<.01. RMSEA was .060 (p = .16). The four-factor model was significantly better than all alternative nested models at p < .001, including an overarching single factor model, representing “depression.” Results support the concept that apathy and depression are discrete constructs. We suggest a “factor based” scoring of the Apathy Scale and Beck Depression Inventory-II that disentangles symptoms related to apathy, depression, overlapping symptoms, and somatic complaints. Such scoring may be important in providing useful information regarding differential treatment options.